ExpreS2ion Biotech Holding (EXPRS2.ST) Stock Analysis & AI Equity Report
ExpreS2ion Biotech Holding (EXPRS2.ST) overview
ExpreS2ion Biotech Holding (EXPRS2.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, ExpreS2ion Biotech Holding reported revenue of SEK 3.7m and operating profit of SEK -52.8m; the year-end share price was 15.90 SEK and market capitalisation was SEK 45.2m. ExpreS2ion Biotech Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ExpreS2ion Biotech Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding AB is a clinical-stage biotechnology company developing active immunotherapies and other biologic drug candidates using its proprietary ExpreS2 protein expression platform. Its pipeline includes an oncology lead asset for HER2-expressing cancers, and partnered infectious disease programmes, while the company also offers contract research services for complex protein expression.
Generate the ExpreS2ion Biotech Holding report
ExpreS2ion Biotech Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ExpreS2ion Biotech Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on ExpreS2ion Biotech Holding
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.